Zealand Pharma's first phase III trial with dasiglucagon for the treatment of congenital hyperinsulinism did not reach its primary endpoint, according to a statement issued by the firm. The company is, however, pleased with some of the partial results in the study and looks forward to developing drugs for the disease going forward.
The firm currently awaits results coming from a different phase III trial involving the rare disease, which entails low blood sugar levels caused by abnormally high insulin levels in the blood. In this trial, dasiglucagon is tested on infants with congenital hyperinsulinism.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and its partner Abbvie in the second half of this year.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
Leo Pharma eczema treatment recommended in two UK countries
After postponing the decision in April, the British medicines council NICE has now ruled that Adtralza can be recommended to treat atopic dermatitis.
Fujifilm invests USD 1.5bn in Danish factory
Japanese firm Fujifilm Diosynth Biotechnologies is investing DKK 11bn (USD 1.5bn) in its factor in Northern Zealand, Denmark. The expansion will provide 450 jobs.
Life science firms are planning USD 6.3bn construction spree in Denmark
Fujifilm’s expansion to its factory in Hillerød means that the life science sector has announced DKK 12bn (USD 1.7bn) in facility investments in Denmark since May.
Global Learning Specialist 
QA Specialist for Product Equipment Qualification 
Specialist within Project Management and Launch, Regulatory Affairs Life Cycle Management 
Principal Laboratory Technologist Medicinal Chemistry 
Senior Scientist for Analytical Development 
Senior Manager/Associate Director, Global Regulatory Affairs, CMC 
KLIFO is looking for a Project Director for our office in Denmark or Germany or Sweden 
Nordic Medical Advisor 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Director Regulatory Affairs 
Senior Electronics Engineer 
Open position for a Clinical Trial Manager to join our team at Nykode!